Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06899152 · ClinicalTrials.gov registry record · NA

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

A NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Montefiore Medical Center.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06899152 is a NA study of Hepatocellular Carcinoma and Liver Cancer that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 40 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06899152, a NA study of Hepatocellular Carcinoma and Liver Cancer, is actively recruiting participants, sponsored by Montefiore Medical Center.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy.

Conditions Studied

Hepatocellular Carcinoma Liver Cancer Cholangiocarcinoma Liver Metastases Hepatocellular Cancer

Interventions

  • DIAGNOSTIC_TEST HepQuant DuO
  • OTHER Multiparametric MRI Scans

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-07-16
Est. Completion 2031-07
Phase NA

Sponsor

Montefiore Medical Center

345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06899152

The ClinicalTrials.gov registry entry for NCT06899152 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which HepQuant DuO is the first listed.

NCT06899152 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06899152 about?

NCT06899152 is a clinical study titled "HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer". This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases re...

What is the current status of trial NCT06899152?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-07-16. Estimated completion is 2031-07.

What conditions does trial NCT06899152 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma, Liver Metastases, Hepatocellular Cancer.

What interventions are being tested in trial NCT06899152?

The interventions under investigation include: HepQuant DuO (DIAGNOSTIC_TEST), Multiparametric MRI Scans (OTHER).

Who is sponsoring clinical trial NCT06899152?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06899152 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Liver Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.